【“下一代减肥药”MariTide有望迎“双面突破”! 安进(AMGN.US)迈向价值重估之路】智通财经APP获悉,美国

智通财经
19 Jun
【“下一代减肥药”MariTide有望迎“双面突破”! 安进(AMGN.US)迈向价值重估之路】智通财经APP获悉,美国生物科技巨头安进公司(AMGN.US)将在2025年6月23日举行的美国糖尿病学会 (ADA) 年会上公布“下一代减肥药物” MariTide 在肥胖症适应症中的II 期(第一部分)完整临床数据。该试验针对肥胖或超重且无Ⅱ型糖尿病的患者开展,为期52周,管理层虽然表示,2024年11月公布的顶线数据已经涵盖了大部分关键数据,但高盛预计本次完整数据披露仍将成为安进乃至整个减肥药领域公司的重要股价上行催化剂,安进将能够提供此前摘要数据中未涵盖的细节和洞见。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10